75 results on '"Talarico, Carmine"'
Search Results
52. Binding Mode Exploration of B1 Receptor Antagonists’ by the Use of Molecular Dynamics and Docking Simulation—How Different Target Engagement Can Determine Different Biological Effects
- Author
-
Gemei, Marica, primary, Talarico, Carmine, additional, Brandolini, Laura, additional, Manelfi, Candida, additional, Za, Lorena, additional, Bovolenta, Silvia, additional, Liberati, Chiara, additional, Del Vecchio, Luigi, additional, Russo, Roberto, additional, Cerchia, Carmen, additional, Allegretti, Marcello, additional, and Beccari, Andrea Rosario, additional
- Published
- 2020
- Full Text
- View/download PDF
53. Computational Studies of SARS-CoV-2 3CLpro: Insights from MD Simulations
- Author
-
Grottesi, Alessandro, primary, Bešker, Neva, additional, Emerson, Andrew, additional, Manelfi, Candida, additional, Beccari, Andrea R., additional, Frigerio, Francesco, additional, Lindahl, Erik, additional, Cerchia, Carmen, additional, and Talarico, Carmine, additional
- Published
- 2020
- Full Text
- View/download PDF
54. Combining Molecular Dynamics and Docking Simulations to Develop Targeted Protocols for Performing Optimized Virtual Screening Campaigns on the hTRPM8 Channel
- Author
-
Talarico, Carmine, primary, Gervasoni, Silvia, additional, Manelfi, Candida, additional, Pedretti, Alessandro, additional, Vistoli, Giulio, additional, and Beccari, Andrea R., additional
- Published
- 2020
- Full Text
- View/download PDF
55. SCoV2-MD: a database for the dynamics of the SARS-CoV-2 proteome and variant impact predictions.
- Author
-
Torrens-Fontanals, Mariona, Peralta-García, Alejandro, Talarico, Carmine, Guixà-González, Ramon, Giorgino, Toni, and Selent, Jana
- Published
- 2022
- Full Text
- View/download PDF
56. Computer-based techniques for lead identification and optimization II: Advanced search methods
- Author
-
Lupia, Antonio, primary, Moraca, Federica, additional, Bagetta, Donatella, additional, Maruca, Annalisa, additional, Ambrosio, Francesca Alessandra, additional, Rocca, Roberta, additional, Catalano, Raffaella, additional, Romeo, Isabella, additional, Talarico, Carmine, additional, Ortuso, Francesco, additional, Artese, Anna, additional, and Alcaro, Stefano, additional
- Published
- 2019
- Full Text
- View/download PDF
57. Computer-based techniques for lead identification and optimization I: Basics
- Author
-
Maruca, Annalisa, primary, Ambrosio, Francesca Alessandra, additional, Lupia, Antonio, additional, Romeo, Isabella, additional, Rocca, Roberta, additional, Moraca, Federica, additional, Talarico, Carmine, additional, Bagetta, Donatella, additional, Catalano, Raffaella, additional, Costa, Giosuè, additional, Artese, Anna, additional, and Alcaro, Stefano, additional
- Published
- 2019
- Full Text
- View/download PDF
58. In Silico Identification of Piperidinyl-amine Derivatives as Novel Dual Binders of Oncogene c-myc/c-Kit G-quadruplexes
- Author
-
Rocca, Roberta, primary, Moraca, Federica, additional, Costa, Giosuè, additional, Talarico, Carmine, additional, Ortuso, Francesco, additional, Da Ros, Silvia, additional, Nicoletto, Giulia, additional, Sissi, Claudia, additional, Alcaro, Stefano, additional, and Artese, Anna, additional
- Published
- 2018
- Full Text
- View/download PDF
59. The Mu.Ta.Lig. Chemotheca: A Community-Populated Molecular Database for Multi-Target Ligands Identification and Compound-Repurposing
- Author
-
Ortuso, Francesco, primary, Bagetta, Donatella, additional, Maruca, Annalisa, additional, Talarico, Carmine, additional, Bolognesi, Maria L., additional, Haider, Norbert, additional, Borges, Fernanda, additional, Bryant, Sharon, additional, Langer, Thierry, additional, Senderowitz, Hanoch, additional, and Alcaro, Stefano, additional
- Published
- 2018
- Full Text
- View/download PDF
60. Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance
- Author
-
Malet, Isabelle, primary, Ambrosio, Francesca A, additional, Subra, Frédéric, additional, Herrmann, Béatrice, additional, Leh, Hervé, additional, Bouger, Marie-Christine, additional, Artese, Anna, additional, Katlama, Christine, additional, Talarico, Carmine, additional, Romeo, Isabella, additional, Alcaro, Stefano, additional, Costa, Giosuè, additional, Deprez, Eric, additional, Calvez, Vincent, additional, Marcelin, Anne-Geneviève, additional, and Delelis, Olivier, additional
- Published
- 2018
- Full Text
- View/download PDF
61. Identification of G-quadruplex DNA/RNA binders: Structure-based virtual screening and biophysical characterization
- Author
-
Rocca, Roberta, primary, Moraca, Federica, additional, Costa, Giosuè, additional, Nadai, Matteo, additional, Scalabrin, Matteo, additional, Talarico, Carmine, additional, Distinto, Simona, additional, Maccioni, Elias, additional, Ortuso, Francesco, additional, Artese, Anna, additional, Alcaro, Stefano, additional, and Richter, Sara N., additional
- Published
- 2017
- Full Text
- View/download PDF
62. A community effort in SARS‐CoV‐2 drug discovery
- Author
-
Schimunek, Johannes, Seidl, Philipp, Elez, Katarina, Hempel, Tim, Le, Tuan, Noé, Frank, Olsson, Simon, Raich, Lluís, Winter, Robin, Gokcan, Hatice, Gusev, Filipp, Gutkin, Evgeny M., Isayev, Olexandr, Kurnikova, Maria G., Narangoda, Chamali H., Zubatyuk, Roman, Bosko, Ivan P., Furs, Konstantin V., Karpenko, Anna D., Kornoushenko, Yury V., Shuldau, Mikita, Yushkevich, Artsemi, Benabderrahmane, Mohammed B., Bousquet‐Melou, Patrick, Bureau, Ronan, Charton, Beatrice, Cirou, Bertrand C., Gil, Gérard, Allen, William J., Sirimulla, Suman, Watowich, Stanley, Antonopoulos, Nick, Epitropakis, Nikolaos, Krasoulis, Agamemnon, Itsikalis, Vassilis, Theodorakis, Stavros, Kozlovskii, Igor, Maliutin, Anton, Medvedev, Alexander, Popov, Petr, Zaretckii, Mark, Eghbal‐Zadeh, Hamid, Halmich, Christina, Hochreiter, Sepp, Mayr, Andreas, Ruch, Peter, Widrich, Michael, Berenger, Francois, Kumar, Ashutosh, Yamanishi, Yoshihiro, Zhang, Kam Y. J., Bengio, Emmanuel, Bengio, Yoshua, Jain, Moksh J., Korablyov, Maksym, Liu, Cheng‐Hao, Marcou, Gilles, Glaab, Enrico, Barnsley, Kelly, Iyengar, Suhasini M., Ondrechen, Mary Jo, Haupt, V. Joachim, Kaiser, Florian, Schroeder, Michael, Pugliese, Luisa, Albani, Simone, Athanasiou, Christina, Beccari, Andrea, Carloni, Paolo, D'Arrigo, Giulia, Gianquinto, Eleonora, Goßen, Jonas, Hanke, Anton, Joseph, Benjamin P., Kokh, Daria B., Kovachka, Sandra, Manelfi, Candida, Mukherjee, Goutam, Muñiz‐Chicharro, Abraham, Musiani, Francesco, Nunes‐Alves, Ariane, Paiardi, Giulia, Rossetti, Giulia, Sadiq, S. Kashif, Spyrakis, Francesca, Talarico, Carmine, Tsengenes, Alexandros, Wade, Rebecca C., Copeland, Conner, Gaiser, Jeremiah, Olson, Daniel R., Roy, Amitava, Venkatraman, Vishwesh, Wheeler, Travis J., Arthanari, Haribabu, Blaschitz, Klara, Cespugli, Marco, Durmaz, Vedat, Fackeldey, Konstantin, Fischer, Patrick D., Gorgulla, Christoph, Gruber, Christian, Gruber, Karl, Hetmann, Michael, Kinney, Jamie E., Padmanabha Das, Krishna M., Pandita, Shreya, Singh, Amit, Steinkellner, Georg, Tesseyre, Guilhem, Wagner, Gerhard, Wang, Zi‐Fu, Yust, Ryan J., Druzhilovskiy, Dmitry S., Filimonov, Dmitry A., Pogodin, Pavel V., Poroikov, Vladimir, Rudik, Anastassia V., Stolbov, Leonid A., Veselovsky, Alexander V., De Rosa, Maria, De Simone, Giada, Gulotta, Maria R., Lombino, Jessica, Mekni, Nedra, Perricone, Ugo, Casini, Arturo, Embree, Amanda, Gordon, D. Benjamin, Lei, David, Pratt, Katelin, Voigt, Christopher A., Chen, Kuang‐Yu, Jacob, Yves, Krischuns, Tim, Lafaye, Pierre, Zettor, Agnès, Rodríguez, M. Luis, White, Kris M., Fearon, Daren, Von Delft, Frank, Walsh, Martin A., Horvath, Dragos, Brooks, Charles L., Falsafi, Babak, Ford, Bryan, García‐Sastre, Adolfo, Yup Lee, Sang, Naffakh, Nadia, Varnek, Alexandre, Klambauer, Günter, and Hermans, Thomas M.
- Abstract
The COVID‐19 pandemic continues to pose a substantial threat to human lives and is likely to do so for years to come. Despite the availability of vaccines, searching for efficient small‐molecule drugs that are widely available, including in low‐ and middle‐income countries, is an ongoing challenge. In this work, we report the results of an open science community effort, the “Billion molecules against COVID‐19 challenge”, to identify small‐molecule inhibitors against SARS‐CoV‐2 or relevant human receptors. Participating teams used a wide variety of computational methods to screen a minimum of 1 billion virtual molecules against 6 protein targets. Overall, 31 teams participated, and they suggested a total of 639,024 molecules, which were subsequently ranked to find ‘consensus compounds’. The organizing team coordinated with various contract research organizations (CROs) and collaborating institutions to synthesize and test 878 compounds for biological activity against proteases (Nsp5, Nsp3, TMPRSS2), nucleocapsid N, RdRP (only the Nsp12 domain), and (alpha) spike protein S. Overall, 27 compounds with weak inhibition/binding were experimentally identified by binding‐, cleavage‐, and/or viral suppression assays and are presented here. Open science approaches such as the one presented here contribute to the knowledge base of future drug discovery efforts in finding better SARS‐CoV‐2 treatments.
- Published
- 2024
- Full Text
- View/download PDF
63. A Comparative Docking Strategy to Identify Polyphenolic Derivatives as Promising Antineoplastic Binders of G-quadruplex DNAc-mycandbcl-2Sequences
- Author
-
Costa, Giosuè, primary, Rocca, Roberta, additional, Moraca, Federica, additional, Talarico, Carmine, additional, Romeo, Isabella, additional, Ortuso, Francesco, additional, Alcaro, Stefano, additional, and Artese, Anna, additional
- Published
- 2016
- Full Text
- View/download PDF
64. Real‐life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling.
- Author
-
Marascio, Nadia, Pavia, Grazia, Romeo, Isabella, Talarico, Carmine, Di Salvo, Sebastiano, Reale, Mariaconcetta, Marano, Vito, Barreca, Giorgio Settimo, Fabiani, Fernanda, Perrotti, Nicola, De Siena, Massimo, Giancotti, Francesca, Gravina, Tiziana, Alcaro, Stefano, Artese, Anna, Torti, Carlo, Liberto, Maria Carla, and Focà, Alfredo
- Abstract
We report a real‐life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D‐R). He had therapy failure at week 12 after the end of treatment. We detected resistance‐associated substitutions (RASs) plus polymorphisms on NS3, NS5A, and NS5B target regions by population sequencing (15% cut‐off) at baseline, at relapse and during follow‐up. About this, NS5A RASs generally persist longer than resistances in the other target genes and may impact treatment outcome. Therefore, to evaluate OMV drug‐resistance mechanism, we studied the acquired RAS plus polymorphisms on NS5A phosphoprotein by computational studies. OMV showed a higher affinity towards baseline and 93H/108 K mutant structure (follow‐up) with respect to 93H/R108 mutant structure (relapse) on phosphoprotein. By Molecular Dynamics simulations (MDs), structural information about the protein stability in presence of OMV were observed. According to our data, molecular modeling approach has proved to be a powerful method to evaluate the impact of these RASs plus specific amino acid (AA) changes on phosphoprotein. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
65. Structural Modeling of New Polymorphism Clusters of HCV Polymerase Isolated from Direct‐Acting Antiviral Naïve Patients: Focus on Dasabuvir and Setrobuvir Binding Affinity.
- Author
-
Romeo, Isabella, Marascio, Nadia, Pavia, Grazia, Talarico, Carmine, Costa, Giosuè, Alcaro, Stefano, Artese, Anna, Torti, Carlo, Liberto, Maria Carla, and Focà, Alfredo
- Subjects
HEPATITIS C ,POLYMERASES ,GENETIC polymorphisms - Abstract
Management of Hepatitis C virus infection changed after the development of direct‐acting antiviral agents, including NS5B polymerase inhibitors. However, the presence of non‐synonymous substitutions could lead to therapy failure. Herein, we analyzed novel polymorphism clusters in NS5B polymerase from Hepatitis C virus (HCV) subtype 1b isolates of direct‐acting antivirals (DAAs) naïve patients by Sanger population sequencing. By means of computational approaches, we investigated the impact of these polymorphisms on the apo‐polymerase stability and on the binding affinity of dasabuvir and setrobuvir. Our thermodynamic and structural analysis highlighted that some mutational patterns could enhance or reduce the drug's affinity if compared to the wild‐type complexes and allowed us to well characterize the binding mode of the known drugs into the NS5B binding pocket. Our computational findings agreed with dasabuvir and setrobuvir in vitro reduced binding affinities against C316N mutant and could be useful in guiding the therapeutic approaches in presence of specific natural polymorphisms on HCV polymerase. 3D representation of the superposed structures of WT (blue cartoon) and C316N (red cartoon) NS5B models obtained from Molecular Dynamics simulations. By comparing the wild‐type and the mutated proteins, structural differences around the residue 316 became more clear in both forms. The morphological information, supported by chemical and steric differences, allows us to better comprehend the enzymatic adaptation which is translating in diverse drug activities. The enzyme is reported as grey carbon surface. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
66. A Comparative Docking Strategy to Identify Polyphenolic Derivatives as Promising Antineoplastic Binders of G-quadruplex DNA c-myc and bcl-2 Sequences.
- Author
-
Costa, Giosuè, Rocca, Roberta, Moraca, Federica, Talarico, Carmine, Romeo, Isabella, Ortuso, Francesco, Alcaro, Stefano, and Artese, Anna
- Subjects
POLYPHENOLS ,QUADRUPLEX nucleic acids ,MOLECULAR docking - Abstract
Polyphenols are compounds ubiquitously expressed in plants and used for their multiple healthy effects in humans as anti-inflammatory, antimicrobial, antiviral, anticancer and immunomodulatory agents. Due to their ability to modulate the activity of multiple targets involved in carcinogenesis, polyphenols can be employed to inhibit the growth of cancer cells. Several studies reported their high affinity to different G-quadruplex DNA structures, including the oncogene promoters c-myc and bcl-2. In this work we applied a structure-based virtual screening approach in order to screen a database of polyphenolic derivatives and human metabolites against both c-myc and bcl-2 DNA G-quadruplex structures. A Delphinidine derivative was identified as the best ' dual' candidate and, after molecular dynamics simulations, resulted able to well stabilize both receptors. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
67. A Comparative Docking Strategy to Identify Polyphenolic Derivatives as Promising Antineoplastic Binders of G‐quadruplex DNA c‐mycand bcl‐2Sequences
- Author
-
Costa, Giosuè, Rocca, Roberta, Moraca, Federica, Talarico, Carmine, Romeo, Isabella, Ortuso, Francesco, Alcaro, Stefano, and Artese, Anna
- Abstract
Polyphenols are compounds ubiquitously expressed in plants and used for their multiple healthy effects in humans as anti‐inflammatory, antimicrobial, antiviral, anticancer and immunomodulatory agents. Due to their ability to modulate the activity of multiple targets involved in carcinogenesis, polyphenols can be employed to inhibit the growth of cancer cells. Several studies reported their high affinity to different G‐quadruplex DNA structures, including the oncogene promoters c‐mycand bcl‐2. In this work we applied a structure‐based virtual screening approach in order to screen a database of polyphenolic derivatives and human metabolites against both c‐mycand bcl‐2DNA G‐quadruplex structures. A Delphinidine derivative was identified as the best “dual” candidate and, after molecular dynamics simulations, resulted able to well stabilize both receptors.
- Published
- 2016
- Full Text
- View/download PDF
68. An extreme-scale virtual screening platform for drug discovery
- Author
-
Gadioli, Davide, Vitali, Emanuele, Ficarelli, Federico, Latini, Chiara, Menelfi, Candida, Talarico, Carmine, Silvano, Cristina, Beccari, Andrea Rosario, and Palermo, Gianluca
- Subjects
Virtual Screening ,HPC ,HPC, Molecular Docking, Virtual Screening ,Molecular Docking - Abstract
Virtual screening is one of the early stages that aims to select a set of promising ligands from a vast chemical library. Molecular Docking is a crucial task in the process of drug discovery and it consists of the estimation of the position of a molecule inside the docking site. In the contest of urgent computing, we designed from scratch the EXSCALATE molecular docking platform to benefit from heterogeneous computation nodes and to avoid scaling issues. This poster presents the achievements and ongoing development of the EXSCALATE platform, together with an example of usage in the context of the COVID-19 pandemic., An abstract of the poster presented at the conference Computing Frontiers 2021.
- Full Text
- View/download PDF
69. Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions
- Author
-
Laura Brandolini, Michele d’Angelo, Rubina Novelli, Vanessa Castelli, Cristina Giorgio, Anna Sirico, Pasquale Cocchiaro, Francesco D’Egidio, Elisabetta Benedetti, Claudia Cristiano, Antonella Bugatti, Anna Ruocco, Pier Giorgio Amendola, Carmine Talarico, Candida Manelfi, Daniela Iaconis, Andrea Beccari, Andreza U. Quadros, Thiago M. Cunha, Arnaldo Caruso, Roberto Russo, Annamaria Cimini, Andrea Aramini, Marcello Allegretti, Brandolini, Laura, D'Angelo, Michele, Novelli, Rubina, Castelli, Vanessa, Giorgio, Cristina, Sirico, Anna, Cocchiaro, Pasquale, D'Egidio, Francesco, Benedetti, Elisabetta, Cristiano, Claudia, Bugatti, Antonella, Ruocco, Anna, Amendola, Pier Giorgio, Talarico, Carmine, Manelfi, Candida, Iaconis, Daniela, Beccari, Andrea, Quadros, Andreza U, Cunha, Thiago M, Caruso, Arnaldo, Russo, Roberto, Cimini, Annamaria, Aramini, Andrea, and Allegretti, Marcello
- Subjects
Cancer Research ,Paclitaxel ,Anaphylatoxin C5a ,Animal ,Immunology ,Peripheral Nervous System Diseases ,Antineoplastic Agents ,Cell Biology ,Rats ,Antineoplastic Agent ,Molecular Docking Simulation ,Mice ,Cellular and Molecular Neuroscience ,Hyperalgesia ,Rat ,Animals ,Receptor, Anaphylatoxin C5a ,Receptor - Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) and hypersensitivity reactions (HSRs) are among the most frequent and impairing side effects of the antineoplastic agent paclitaxel. Here, we demonstrated that paclitaxel can bind and activate complement component 5a receptor 1 (C5aR1) and that this binding is crucial in the etiology of paclitaxel-induced CIPN and anaphylaxis. Starting from our previous data demonstrating the role of interleukin (IL)-8 in paclitaxel-induced neuronal toxicity, we searched for proteins that activate IL-8 expression and, by using the Exscalate platform for molecular docking simulations, we predicted the high affinity of C5aR1 with paclitaxel. By in vitro studies, we confirmed the specific and competitive nature of the C5aR1-paclitaxel binding and found that it triggers intracellularly the NFkB/P38 pathway and c-Fos. In F11 neuronal cells and rat dorsal root ganglia, C5aR1 inhibition protected from paclitaxel-induced neuropathological effects, while in paclitaxel-treated mice, the absence (knock-out mice) or the inhibition of C5aR1 significantly ameliorated CIPN symptoms—in terms of cold and mechanical allodynia—and reduced the chronic pathological state in the paw. Finally, we found that C5aR1 inhibition can counteract paclitaxel-induced anaphylactic cytokine release in macrophages in vitro, as well as the onset of HSRs in mice. Altogether these data identified C5aR1 as a key mediator and a new potential pharmacological target for the prevention and treatment of CIPN and HSRs induced by paclitaxel.
- Published
- 2022
70. Natural Compounds Inhibit SARS-CoV-2 nsp13 Unwinding and ATPase Enzyme Activities
- Author
-
Angela Corona, Krzysztof Wycisk, Carmine Talarico, Candida Manelfi, Jessica Milia, Rolando Cannalire, Francesca Esposito, Philip Gribbon, Andrea Zaliani, Daniela Iaconis, Andrea R. Beccari, Vincenzo Summa, Marcin Nowotny, Enzo Tramontano, Publica, Corona, Angela, Wycisk, Krzysztof, Talarico, Carmine, Manelfi, Candida, Milia, Jessica, Cannalire, Rolando, Esposito, Francesca, Gribbon, Philip, Zaliani, Andrea, Iaconis, Daniela, Beccari, Andrea R., Summa, Vincenzo, Nowotny, Marcin, and Tramontano, Enzo
- Subjects
Pharmacology ,helicase ,nsp13 ,SARS-CoV-2 inhibition nsp13 helicase flavonoid inhibitors drug development unwinding inhibition ,Pharmacology (medical) ,flavonoid inhibitors ,SARS-CoV-2 inhibition ,drug development ,unwinding inhibition - Abstract
SARS-CoV-2 infection is still spreading worldwide, and new antiviral therapies are an urgent need to complement the approved vaccine preparations. SARS-CoV-2 nps13 helicase is a validated drug target participating in the viral replication complex and possessing two associated activities: RNA unwinding and 5′-triphosphatase. In the search of SARS-CoV-2 direct antiviral agents, we established biochemical assays for both SARS-CoV-2 nps13-associated enzyme activities and screened both in silico and in vitro a small in-house library of natural compounds. Myricetin, quercetin, kaempferol, and flavanone were found to inhibit the SARS-CoV-2 nps13 unwinding activity at nanomolar concentrations, while licoflavone C was shown to block both SARS-CoV-2 nps13 activities at micromolar concentrations. Mode of action studies showed that all compounds are nsp13 noncompetitive inhibitors versus ATP, while computational studies suggested that they can bind both nucleotide and 5′-RNA nsp13 binding sites, with licoflavone C showing a unique pattern of interaction with nsp13 amino acid residues. Overall, we report for the first time natural flavonoids as selective inhibitors of SARS-CoV-2 nps13 helicase with low micromolar activity.
- Published
- 2022
71. Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein
- Author
-
Alessandro Grottesi, Nico Sanna, Ingrid Guarnetti Prandi, Carmen Cerchia, Nabil Abid, Stefano Borocci, Giovanni Chillemi, Andrea R. Beccari, Carmine Talarico, Borocci, Stefano, Cerchia, Carmen, Grottesi, Alessandro, Sanna, Nico, Prandi, Ingrid Guarnetti, Abid, Nabil, Beccari, Andrea R, Chillemi, Giovanni, and Talarico, Carmine
- Subjects
Mutant ,01 natural sciences ,Epitope ,Epitopes ,Biology (General) ,Polysaccharide ,Protein Interaction Domains and Motif ,Spectroscopy ,Genetics ,chemistry.chemical_classification ,0303 health sciences ,variants ,010304 chemical physics ,molecular dynamic ,General Medicine ,3. Good health ,Computer Science Applications ,Chemistry ,Spike Glycoprotein, Coronavirus ,Human ,Protein Domain ,QH301-705.5 ,Protein domain ,Virulence ,Molecular Dynamics Simulation ,Biology ,Article ,Catalysis ,Virus ,Inorganic Chemistry ,03 medical and health sciences ,Protein Domains ,Polysaccharides ,Viral entry ,0103 physical sciences ,Humans ,Protein Interaction Domains and Motifs ,Physical and Theoretical Chemistry ,Molecular Biology ,QD1-999 ,030304 developmental biology ,Binding Sites ,SARS-CoV-2 ,Organic Chemistry ,Binding Site ,Wild type ,COVID-19 ,Hydrogen Bonding ,spike ,Antibodies, Neutralizing ,United Kingdom ,molecular dynamics ,variant ,chemistry ,Glycoprotein ,Spike Glycoprotein, Coronaviru - Abstract
The COVID-19 pandemic is caused by SARS-CoV-2. Currently, most of the research efforts towards the development of vaccines and antibodies against SARS-CoV-2 were mainly focused on the spike (S) protein, which mediates virus entry into the host cell by binding to ACE2. As the virus SARS-CoV-2 continues to spread globally, variants have emerged, characterized by multiple mutations of the S glycoprotein. Herein, we employed microsecond-long molecular dynamics simulations to study the impact of the mutations of the S glycoprotein in SARS-CoV-2 Variant of Concern 202012/01 (B.1.1.7), termed the “UK variant”, in comparison with the wild type, with the aim to decipher the structural basis of the reported increased infectivity and virulence. The simulations provided insights on the different dynamics of UK and wild-type S glycoprotein, regarding in particular the Receptor Binding Domain (RBD). In addition, we investigated the role of glycans in modulating the conformational transitions of the RBD. The overall results showed that the UK mutant experiences higher flexibility in the RBD with respect to wild type, this behavior might be correlated with the increased transmission reported for this variant. Our work also adds useful structural information on antigenic “hotspots” and epitopes targeted by neutralizing antibodies.
- Published
- 2021
- Full Text
- View/download PDF
72. The Mu.Ta.Lig. Chemotheca: A Community-Populated Molecular Database for Multi-Target Ligands Identification and Compound-Repurposing
- Author
-
Francesco Ortuso, Norbert Haider, Stefano Alcaro, Donatella Bagetta, Fernanda Borges, Sharon D. Bryant, Maria Laura Bolognesi, Annalisa Maruca, Thierry Langer, Carmine Talarico, Hanoch Senderowitz, Ortuso, Francesco, Bagetta, Donatella, Maruca, Annalisa, Talarico, Carmine, Bolognesi, Maria L., Haider, Norbert, Borges, Fernanda, Bryant, Sharon, Langer, Thierry, Senderowitz, Hanoch, and Alcaro, Stefano
- Subjects
0301 basic medicine ,Computer science ,Multi-target drug ,Permission ,computer.software_genre ,Set (abstract data type) ,lcsh:Chemistry ,03 medical and health sciences ,Upload ,molecular descriptors ,Data retrieval ,Pybel ,Technology Report ,LAMP server ,Repurposing ,Information exchange ,Graphical user interface ,scientific collaboration ,Database ,drug repurposing ,business.industry ,Chemistry (all) ,General Chemistry ,multi-target drugs ,Identification (information) ,Chemistry ,molecular database ,030104 developmental biology ,lcsh:QD1-999 ,openbabel ,business ,computer ,Molecular descriptor - Abstract
For every lead compound developed in medicinal chemistry research, numerous other inactive or less active candidates are synthetized/isolated and tested. The majority of these compounds will not be selected for further development due to a sub-optimal pharmacological profile. However, some poorly active or even inactive compounds could live a second life if tested against other targets. Thus, new therapeutic opportunities could emerge and synergistic activities could be identified and exploited for existing compounds by sharing information between researchers who are working on different targets. The Mu.Ta.Lig (Multi-Target Ligand) Chemotheca database aims to offer such opportunities by facilitating information exchange among researchers worldwide. After a preliminary registration, users can (a) virtually upload structures and activity data for their compounds with corresponding, and eventually known activity data, and (b) search for other available compounds uploaded by the users community. Each piece of information about given compounds is owned by the user who initially uploaded it and multiple ownership is possible (this occurs if different users uploaded the same compounds or information pertaining to the same compounds). A web-based graphical user interface has been developed to assist compound uploading, compounds searching and data retrieval. Physico-chemical and ADME properties as well as substructure-based PAINS evaluations are computed on the fly for each uploaded compound. Samples of compounds that match a set of search criteria and additional data on these compounds could be requested directly from their owners with no mediation by the Mu.Ta.Lig Chemotheca team. Guest access provides a simplified search interface to retrieve only basic information such as compound IDs and related 2D or 3D chemical structures. Moreover, some compounds can be hidden to Guest users according to an owner's decision. In contrast, registered users have full access to all of the Chemotheca data including the permission to upload new compounds and/or update experimental/theoretical data (e.g., activities against new targets tested) related to already stored compounds. In order to facilitate scientific collaborations, all available data are connected to the corresponding owner's email address (available for registered users only). The Chemotheca web site is accessible at http://chemotheca.unicz.it.
- Published
- 2018
73. Approaching Pharmacological Space: Events and Components.
- Author
-
Vistoli G, Talarico C, Vittorio S, Lunghini F, Mazzolari A, Beccari A, and Pedretti A
- Subjects
- Ligands, Humans, Protein Binding, Proteins chemistry, Proteins metabolism, Drug Discovery methods, Binding Sites, Molecular Docking Simulation
- Abstract
The pharmacological space comprises all the dynamic events that determine the bioactivity (and/or the metabolism and toxicity) of a given ligand. The pharmacological space accounts for the structural flexibility and property variability of the two interacting molecules as well as for the mutual adaptability characterizing their molecular recognition process. The dynamic behavior of all these events can be described by a set of possible states (e.g., conformations, binding modes, isomeric forms) that the simulated systems can assume. For each monitored state, a set of state-dependent ligand- and structure-based descriptors can be calculated. Instead of considering only the most probable state (as routinely done), the pharmacological space proposes to consider all the monitored states. For each state-dependent descriptor, the corresponding space can be evaluated by calculating various dynamic parameters such as mean and range values.The reviewed examples emphasize that the pharmacological space can find fruitful applications in structure-based virtual screening as well as in toxicity prediction. In detail, in all reported examples, the inclusion of the pharmacological space parameters enhances the resulting performances. Beneficial effects are obtained by combining both different binding modes to account for ligand mobility and different target structures to account for protein flexibility/adaptability.The proposed computational workflow that combines docking simulations and rescoring analyses to enrich the arsenal of docking-based descriptors revealed a general applicability regardless of the considered target and utilized docking engine. Finally, the EFO approach that generates consensus models by linearly combining various descriptors yielded highly performing models in all discussed virtual screening campaigns., (© 2025. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2025
- Full Text
- View/download PDF
74. MEDIATE - Molecular DockIng at homE: Turning collaborative simulations into therapeutic solutions.
- Author
-
Vistoli G, Manelfi C, Talarico C, Fava A, Warshel A, Tetko IV, Apostolov R, Ye Y, Latini C, Ficarelli F, Palermo G, Gadioli D, Vitali E, Varriale G, Pisapia V, Scaturro M, Coletti S, Gregori D, Gruffat D, Leija E, Hessenauer S, Delbianco A, Allegretti M, and Beccari AR
- Subjects
- Humans, Molecular Docking Simulation, Proteins, Antiviral Agents, SARS-CoV-2, COVID-19
- Abstract
Introduction: Collaborative computing has attracted great interest in the possibility of joining the efforts of researchers worldwide. Its relevance has further increased during the pandemic crisis since it allows for the strengthening of scientific collaborations while avoiding physical interactions. Thus, the E4C consortium presents the MEDIATE initiative which invited researchers to contribute via their virtual screening simulations that will be combined with AI-based consensus approaches to provide robust and method-independent predictions. The best compounds will be tested, and the biological results will be shared with the scientific community., Areas Covered: In this paper, the MEDIATE initiative is described. This shares compounds' libraries and protein structures prepared to perform standardized virtual screenings. Preliminary analyses are also reported which provide encouraging results emphasizing the MEDIATE initiative's capacity to identify active compounds., Expert Opinion: Structure-based virtual screening is well-suited for collaborative projects provided that the participating researchers work on the same input file. Until now, such a strategy was rarely pursued and most initiatives in the field were organized as challenges. The MEDIATE platform is focused on SARS-CoV-2 targets but can be seen as a prototype which can be utilized to perform collaborative virtual screening campaigns in any therapeutic field by sharing the appropriate input files.
- Published
- 2023
- Full Text
- View/download PDF
75. The SARS-CoV-2 spike protein binds and modulates estrogen receptors.
- Author
-
Solis O, Beccari AR, Iaconis D, Talarico C, Ruiz-Bedoya CA, Nwachukwu JC, Cimini A, Castelli V, Bertini R, Montopoli M, Cocetta V, Borocci S, Prandi IG, Flavahan K, Bahr M, Napiorkowski A, Chillemi G, Ooka M, Yang X, Zhang S, Xia M, Zheng W, Bonaventura J, Pomper MG, Hooper JE, Morales M, Rosenberg AZ, Nettles KW, Jain SK, Allegretti M, and Michaelides M
- Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein binds angiotensin-converting enzyme 2 (ACE2) at the cell surface, which constitutes the primary mechanism driving SARS-CoV-2 infection. Molecular interactions between the transduced S and endogenous proteins likely occur post-infection, but such interactions are not well understood. We used an unbiased primary screen to profile the binding of full-length S against >9,000 human proteins and found significant S-host protein interactions, including one between S and human estrogen receptor alpha (ERα). After confirming this interaction in a secondary assay, we used bioinformatics, supercomputing, and experimental assays to identify a highly conserved and functional nuclear receptor coregulator (NRC) LXD-like motif on the S2 subunit and an S-ERα binding mode. In cultured cells, S DNA transfection increased ERα cytoplasmic accumulation, and S treatment induced ER-dependent biological effects and ACE2 expression. Noninvasive multimodal PET/CT imaging in SARS-CoV-2-infected hamsters using [
18 F]fluoroestradiol (FES) localized lung pathology with increased ERα lung levels. Postmortem experiments in lung tissues from SARS-CoV-2-infected hamsters and humans confirmed an increase in cytoplasmic ERα expression and its colocalization with S protein in alveolar macrophages. These findings describe the discovery and characterization of a novel S-ERα interaction, imply a role for S as an NRC, and are poised to advance knowledge of SARS-CoV-2 biology, COVID-19 pathology, and mechanisms of sex differences in the pathology of infectious disease.- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.